Burak Alper Zengin

Dr. Burak Alper Zengin

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
AYAnıl Yıldız
Anıl Yıldız
BZBurak Alper Zengin
Burak Alper Zengin
MMMartin Mildanoğlu
Martin Mildanoğlu
BUBedirhan Ulufer
Bedirhan Ulufer
ABAhmet Bilici
Ahmet Bilici
NANaziye Ak
Naziye Ak
Background/Objectives: ABO/Rh blood groups and systemic inflammation are each linked to cancer biology and prognosis, yet their combined and interactive prognostic value has not been clarified in small-cell lung cancer (SCLC). We investigated the distribution of ABO/Rh blood groups in SCLC, their association with baseline complete blood count (CBC)–derived inflammatory indices, and the prognostic significance of blood group–inflammation interactions for treatment response and survival outcomes. Methods: This retrospective study included 158 patients with SCLC with available ABO/Rh typing and pretreatment CBC data. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune–inflammation index (SII), and systemic inflammation response index (SIRI) were calculated using standard formulas. Treatment response was assessed according to RECIST v1.1 and categorized as response (CR/PR) versus non-response (SD/PD). Progression-free survival (PFS) and overall survival (OS) were analyzed using Cox regression models incorporating interaction terms. Results: Patients with blood group O exhibited consistently lower baseline inflammatory indices compared with non-O blood groups. Non-O blood group status and higher SIRI independently predicted chemoradiotherapy non-response. Among the evaluated indices, SIRI demonstrated superior diagnostic performance compared with SII, NLR, and PLR. Similarly, non-O blood group status and higher SIRI were independently associated with increased risks of progression and mortality. In joint analyses, compared with blood group O and low SIRI (reference), the highest risk of progression was observed in patients with blood group AB × high SIRI (HR 14.67), followed by blood groups A × high SIRI (HR 10.38) and B × high SIRI (HR 7.95). A similar pattern was observed for mortality, with the highest risk in patients with blood group AB × high SIRI (HR 22.76), followed by blood groups A × high SIRI (HR 13.93) and B × high SIRI (HR 12.41). Conclusions: ABO blood group is associated with distinct inflammatory profiles in SCLC. Elevated SIRI independently predicts treatment non-response and adverse survival, and its prognostic effect varies by blood group, underscoring the role of host biology in modulating systemic inflammation.

23 October 2023 in Infectious Diseases in Clinical Practice
Verified
Journal Article
Closed access
MKMiraç Öz Kahya
Miraç Öz Kahya
NANasser E. Absieha
Nasser E. Absieha
UDUmut Dilegelen
Umut Dilegelen
BZBurak Alper Zengin
Burak Alper Zengin
KGKaan Gündüz
Kaan Gündüz
SSSevgi Saryal
Sevgi Saryal
Syphilis is a multisystem infection caused by the spirochete Treponema pallidum. A 63-year-old man admitted to the hospital with chest pain and rashes on the chest wall and hands for 14 days. Thorax computed tomography revealed multiple nodular shadows in the bilateral lower lobes of the lung. Skin lesions were considered compatible with secondary syphilis. The antibody test for syphilis was positive. Screening for other associated sexually transmitted diseases (serology for HIV, hepatitis C, and hepatitis B) was negative. A specific therapy with crystallized penicillin G 2.4 MIU was applied. The key features for secondary syphilis diagnosis were positive serologic tests for syphilis and complete recovery on thorax computed tomography after antisyphilitic treatment. Pulmonary involvement in secondary syphilis is considered a rare occurrence.